Last edition
News about "Thyroid Eye Disease"
Eli Lilly to Acquire Merida Biosciences in Deal Valued at Up to USD 2.875 Billion
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion to advance precision therapies targeting disease-causing autoantibodies.
Thyroid Eye Disease | 01/09/2026 | By News Bureau | 117
Roche's Enspryng Receives FDA Priority Review for Thyroid Eye Disease
Roche's Enspryng has received FDA Priority Review for thyroid eye disease after Phase 3 studies demonstrated clinically meaningful improvements in eye bulging, disease activity and double vision, with a regulatory decision expected by October 2026.
Thyroid Eye Disease | 01/07/2026 | By News Bureau | 133
US FDA approves Viridian's Lumvoa for treatment of thyroid eye disease
Viridian Therapeutics secures US FDA approval for Lumvoa, the first IGF-1R antagonist approved to treat both active and chronic thyroid eye disease, with commercial launch set to begin immediately.
Thyroid Eye Disease | 30/06/2026 | By News Bureau | 102
US FDA approves Viridian's Lumvoa for treatment of thyroid eye disease
Viridian Therapeutics secures US FDA approval for Lumvoa, the first IGF-1R antagonist approved to treat both active and chronic thyroid eye disease, with commercial launch set to begin immediately.
Thyroid Eye Disease | 30/06/2026 | By News Bureau | 102
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy